Related Experiment Video
Updated: Jul 10, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute
M Roffi1, D P Chew, D Mukherjee
1Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Circulation
|December 6, 2001
Summary
Diabetic patients with acute coronary syndromes (ACS) benefit significantly from platelet glycoprotein (GP) IIb/IIIa inhibition, experiencing reduced mortality. This survival benefit is particularly pronounced in those undergoing percutaneous coronary intervention (PCI).
Area of Science:
- Cardiology
- Pharmacology
- Diabetology
Background:
- Diabetes mellitus is a significant risk factor for poor outcomes following acute coronary syndromes (ACS).
- Diabetic patients may exhibit increased platelet aggregation, suggesting a potential benefit from antiplatelet therapies.
- Platelet glycoprotein (GP) IIb/IIIa receptor inhibition is a key therapeutic strategy in ACS management.
Purpose of the Study:
- To investigate the efficacy of platelet GP IIb/IIIa receptor inhibition in diabetic patients with ACS.
- To determine if diabetic status influences the survival benefit of GP IIb/IIIa inhibitors in ACS.
Main Methods:
- A meta-analysis was conducted using data from six large-scale ACS trials involving platelet GP IIb/IIIa inhibitors.
- Diabetic and non-diabetic patient populations were analyzed separately.
- Outcomes, including 30-day mortality, were assessed, with a focus on patients undergoing percutaneous coronary intervention (PCI).
Main Results:
- In 6458 diabetic patients, GP IIb/IIIa inhibition significantly reduced 30-day mortality (6.2% to 4.6%, OR 0.74, P=0.007).
- No survival benefit was observed in 23,072 non-diabetic patients (3.0% vs. 3.0%).
- The interaction between GP IIb/IIIa inhibition and diabetes was statistically significant (P=0.036).
- Among diabetic patients undergoing PCI (1279), mortality was significantly reduced (4.0% to 1.2%, OR 0.30, P=0.002).
Conclusions:
- Intravenous platelet GP IIb/IIIa inhibitors significantly reduce 30-day mortality in diabetic patients with non-ST-segment-elevation ACS.
- The survival benefit of GP IIb/IIIa inhibitors appears greater in diabetic patients undergoing PCI.
- Strong consideration for using GP IIb/IIIa inhibitors is recommended for diabetic patients experiencing ACS.
Related Concept Videos
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.